Equities

ASKA Pharmaceutical Holdings Co Ltd

ASKA Pharmaceutical Holdings Co Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded1.87k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 16 2024 13:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year ASKA Pharmaceutical Holdings Co Ltd grew revenues 3.94% from 60.46bn to 62.84bn while net income improved 78.01% from 4.24bn to 7.55bn.
Gross margin49.66%
Net profit margin11.70%
Operating margin10.37%
Return on assets8.38%
Return on equity12.30%
Return on investment10.69%
More ▼

Cash flow in JPYView more

In 2024, ASKA Pharmaceutical Holdings Co Ltd did not generate a significant amount of cash. However, Cash Flow from Investing totalled 1.71bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 1.49bn in cash from operations while cash used for financing totalled 3.94bn.
Cash flow per share348.58
Price/Cash flow per share6.66
Book value per share2,235.47
Tangible book value per share2,115.35
More ▼

Balance sheet in JPYView more

ASKA Pharmaceutical Holdings Co Ltd has a Debt to Total Capital ratio of 11.54%, a lower figure than the previous year's 13.65%.
Current ratio2.66
Quick ratio1.61
Total debt/total equity0.1305
Total debt/total capital0.1154
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)1.12%
Div growth rate (5 year)23.36%
Payout ratio (TTM)15.32%
EPS growth(5 years)33.95
EPS (TTM) vs
TTM 1 year ago
69.80
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.